ICON Public Limited Company (ICLR)
| Market Cap | 14.29B -2.8% |
| Revenue (ttm) | 8.29B +3.3% |
| Net Income | 27.04M -96.4% |
| EPS | 0.35 -96.2% |
| Shares Out | 77.15M |
| PE Ratio | 530.51 |
| Forward PE | 16.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,022,544 |
| Open | 184.25 |
| Previous Close | 185.43 |
| Day's Range | 179.89 - 185.57 |
| 52-Week Range | 66.57 - 203.91 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 188.24 (+1.6%) |
| Earnings Date | Oct 27, 2026 |
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access ... [Read more]
Financial Performance
In 2025, ICLR's revenue was $8.25 billion, an increase of 0.76% compared to the previous year's $8.19 billion. Earnings were $214.04 million, a decrease of -70.56%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ICLR stock is "Buy." The 12-month stock price target is $188.24, which is an increase of 1.60% from the latest price.
News
Icon upgraded to Neutral from Underperform at BofA
BofA analyst Lu Li upgraded Icon (ICLR) to Neutral from Underperform with a price target of $185, up from $160, as a healthier CRO demand backdrop and sustained direct-fee bookings…
ICON Schedules Third Quarter 2026 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON Schedules Third Quarter 2026 Earnings Conference Call.
Icon resumed with a Neutral at UBS
UBS analyst Kevin Caliendo resumed coverage of Icon (ICLR) with a Neutral rating and $195 price target UBS assumed coverage of the contract research organization industry with a constructive view…
Icon price target lowered to $175 from $180 at Citi
Citi analyst Albert Hu lowered the firm’s price target on Icon (ICLR) to $175 from $180 and keeps a Neutral rating on the shares.
Icon announces private offering of notes
ICON (ICLR) announced that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company, intends to offer one or more series of senior notes, in a private offering with registration r...
ICON Announces Private Offering of Notes
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Co...
ICON Announces Results of Annual General Meeting
DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.
Icon price target raised to $160 from $150 at BofA
BofA raised the firm’s price target on Icon (ICLR) to $160 from $150 and keeps an Underperform rating on the shares. The firm updated its models for Q2 results and…
Icon price target raised to $194 from $192 at Baird
Baird raised the firm’s price target on Icon (ICLR) to $194 from $192 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results. Published…
Icon price target raised to $180 from $165 at Citi
Citi analyst Brendan Digan raised the firm’s price target on Icon (ICLR) to $180 from $165 and keeps a Neutral rating on the shares.
ICON Public Limited Company Earnings Call Transcript: Q2 2026
Q2 2026 saw strong bookings, solid revenue growth, and disciplined cost control, with elevated pass-through activity impacting margins. Strategic investments in AI and Asia-Pacific expansion support long-term growth, while full-year guidance is reaffirmed amid a constructive demand environment.
ICON Public Limited Company Earnings release: Q2 2026
ICON Public Limited Company released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q2 2026
ICON Public Limited Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Icon reports Q2 adjusted EPS $2.56 consensus $2.52
Reports Q2 revenue $2.063B, consensus $2.01B. CEO, Mr. Barry Balfe commented, “ICON’s (ICLR) second quarter results reflect measured progress, as disciplined cost management offset anticipated operati...
ICON Reports Second Quarter 2026 Results
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the second quarter ended June 30, 2026.
Icon announces multi-year collaboration with Anthropic
ICON (ICLR) announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. Through this collaboration, ICON will work closely with Anthropic...
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude's AI capabilities across the clinical trial lifecycle. The collaboration furt...
ICON Schedules Second Quarter 2026 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON Schedules Second Quarter 2026 Earnings Conference Call.
Icon upgraded to Buy from Hold at Truist
Truist upgraded Icon (ICLR) to Buy from Hold with a price target of $207, up from $159. The firm sees from “meaningful upside” to Icon’s 2027 consensus estimates. Truist says…
Icon price target raised to $190 from $180 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Icon (ICLR) to $190 from $180 and keeps an Outperform rating on the shares. The company reported a solid quarter,…
Icon upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Icon (ICLR) to Outperform from Sector Perform with a price target of $185, up from $126. The firm says the company’s two consecutive quarters of “strong” bookings,…
Icon price target raised to $187 from $160 at BMO Capital
BMO Capital raised the firm’s price target on Icon (ICLR) to $187 from $160 and keeps an Outperform rating on the shares after it’s solid Q1 results. The firm cites…
Icon price target raised to $155 from $130 at JPMorgan
JPMorgan raised the firm’s price target on Icon (ICLR) to $155 from $130 and keeps a Neutral rating on the shares. The company’s fiscal Q1 report brought an “encouraging continuation”…
Icon price target raised to $197 from $164 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Icon (ICLR) to $197 from $164 and keeps a Buy rating on the shares. The firm said they see…
Icon price target raised to $150 from $125 at BofA
BofA raised the firm’s price target on Icon (ICLR) to $150 from $125 and keeps an Underperform rating on the shares. Q1 earnings were positive, though “expected/unsurprising,” but the market…